What is Integrium?
Founded in 1998 and headquartered in Tustin, California, Integrium operates as a full-service clinical proof of concept firm. The company specializes in assisting micro cap, small cap, and privately held biotechs, both in the generic and innovator spaces, to achieve critical clinical data and enhance their capital standing. Integrium's therapeutic expertise spans a broad range of areas including Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Additionally, the firm possesses secondary specialties in Schedule 2 drugs and Oncology, positioning it as a versatile partner in drug development.
How much funding has Integrium raised?
Integrium has raised a total of $956K across 2 funding rounds:
Debt
$350K
Debt
$606K
Debt (2020): $350K with participation from PPP
Debt (2021): $606K led by PPP
What's next for Integrium?
The recent major strategic investment signifies a period of accelerated growth and expansion for Integrium. This influx of capital is expected to bolster the company's capabilities in generating robust clinical data, potentially enabling further development and commercialization pathways for its biotech clients. Integrium's focus on diverse therapeutic areas and its established track record suggest a strategic positioning for future advancements in the pharmaceutical and biotechnology sectors.
See full Integrium company page
